Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and Their Metabolites After Application of MC2-01 Cream in Adolescents With Extensive Psoriasis Vulgaris

Trial Profile

A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and Their Metabolites After Application of MC2-01 Cream in Adolescents With Extensive Psoriasis Vulgaris

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary) ; Betamethasone-dipropionate/calcipotriol (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacodynamics
  • Sponsors MC2 Therapeutics
  • Most Recent Events

    • 20 Dec 2021 This trial has been completed in Hungary (end date: 2020-05-27) according to European Clinical Trials Database record.
    • 07 Mar 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record. (Global end date:2020-12-11)
    • 01 Feb 2021 Status changed from active, no longer recruiting to discontinued due to lack of recruitment.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top